Published in Antimicrob Agents Chemother on August 29, 2011
Bioinformatic analysis of HIV-1 entry and pathogenesis. Curr HIV Res (2014) 0.83
HIV-1 envelope glycoprotein variable loops are indispensable for envelope structural integrity and virus entry. PLoS One (2013) 0.82
Hybrid approach for predicting coreceptor used by HIV-1 from its V3 loop amino acid sequence. PLoS One (2013) 0.82
HIV-1 tropism dynamics and phylogenetic analysis from longitudinal ultra-deep sequencing data of CCR5- and CXCR4-using variants. PLoS One (2014) 0.81
X4 viruses are frequently archived in patients with long-term HIV infection but do not seem to influence the "inflamm-aging" process. BMC Infect Dis (2013) 0.80
Defining differential genetic signatures in CXCR4- and the CCR5-utilizing HIV-1 co-linear sequences. PLoS One (2014) 0.78
Mutations in variable domains of the HIV-1 envelope gene can have a significant impact on maraviroc and vicriviroc resistance. AIDS Res Ther (2013) 0.76
HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations. Can J Infect Dis Med Microbiol (2013) 0.76
Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure. Antimicrob Agents Chemother (2016) 0.75
Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients. In Vivo (2017) 0.75
A diagnostic HIV-1 tropism system based on sequence relatedness. J Clin Microbiol (2014) 0.75
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol (1992) 7.92
Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med (2008) 7.31
Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol (1997) 5.18
Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol (2003) 4.56
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis (2010) 3.47
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis (2007) 3.05
Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology (2001) 2.74
Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther (2007) 2.49
European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis (2011) 2.47
A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol (1993) 2.46
Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses (2007) 2.19
Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol (2002) 2.19
Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis (2005) 2.07
N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem (2001) 2.07
Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol (1998) 2.01
Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS (2010) 1.83
Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J Clin Microbiol (1995) 1.79
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis (2009) 1.79
Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J Virol (1996) 1.55
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother (2010) 1.53
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology (2007) 1.41
CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS (2010) 1.32
HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes. J Leukoc Biol (2006) 1.31
Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J Gen Virol (2005) 1.16
Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology (2008) 1.04
Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection. Infect Genet Evol (2009) 1.01
How HIV changes its tropism: evolution and adaptation? Curr Opin HIV AIDS (2009) 0.98
Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. AIDS (2008) 0.97
Length variation of glycoprotein 120 V2 region in relation to biological phenotypes and coreceptor usage of primary HIV type 1 isolates. AIDS Res Hum Retroviruses (2001) 0.96
Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors. AIDS (2010) 0.95
Improved prediction of HIV‐1 coreceptor usage with sequence information from the second hypervariable loop of gp120. J Infect Dis (2010) 0.92
HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples. Virus Res (2007) 0.90
Are the proposed env mutations actually associated with resistance to maraviroc? J Acquir Immune Defic Syndr (2010) 0.79
V3 sequences and paired HIV isolates from 52 non-subtype B HIV type 1-infected patients. AIDS Res Hum Retroviruses (2010) 0.78
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. Clin Infect Dis (2010) 2.32
Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin. Hepatology (2014) 2.08
Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. Clin Infect Dis (2011) 1.97
Rapid on-site evaluation of transbronchial aspirates in the diagnosis of hilar and mediastinal adenopathy: a randomized trial. Chest (2010) 1.89
HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol (2012) 1.69
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS (2003) 1.45
Do adherence rates and glaucomatous visual field progression correlate? Eur J Ophthalmol (2011) 1.29
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr (2006) 1.27
Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr (2003) 1.25
Prevalence of Plasmodium spp. in malaria asymptomatic African migrants assessed by nucleic acid sequence based amplification. Malar J (2009) 1.22
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One (2010) 1.13
Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients. J Infect Dis (2003) 1.13
Increasing clinical virulence in two decades of the Italian HIV epidemic. PLoS Pathog (2009) 1.10
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol (2012) 1.10
Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis (2006) 1.09
Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion (2010) 1.06
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol (2010) 1.06
Surveillance of hospital-acquired infections: a model for settings with resource constraints. Am J Infect Control (2006) 1.03
Intermittent flushing with heparin versus saline for maintenance of peripheral intravenous catheters in a medical department: a pragmatic cluster-randomized controlled study. Worldviews Evid Based Nurs (2012) 1.02
QuantiFERON-TB Gold In-Tube test (QFT-GIT) for the screening of latent tuberculosis in recent immigrants to Italy. New Microbiol (2009) 1.02
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J Acquir Immune Defic Syndr (2003) 1.01
Community-acquired pneumonia. Curr Opin Pulm Med (2009) 1.01
Electrical and autonomic cardiac function in patients with Dravet syndrome. Epilepsia (2011) 1.01
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis (2005) 0.99
FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis. Eur J Nucl Med Mol Imaging (2012) 0.98
Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur J Ophthalmol (2012) 0.96
Co-receptor switch during HAART is independent of virological success. J Med Virol (2009) 0.96
Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study. J Interferon Cytokine Res (2008) 0.96
Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. J Acquir Immune Defic Syndr (2016) 0.95
HIV-1 subtypes and circulating recombinant forms (CRFs) from HIV-infected patients residing in two regions of central and southern Italy. J Med Virol (2005) 0.93
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol (2012) 0.93
Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3. Curr HIV Res (2010) 0.93
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology (2014) 0.92
Prevalence of HBV-genotypes in immigrants affected by HBV-related chronic active hepatitis. Arq Gastroenterol (2007) 0.92
Population-based surveillance of infectious endocarditis in an Italian region. Arch Intern Med (2009) 0.92
Performance characteristics and predictors of yield from transbronchial needle aspiration in the diagnosis of peripheral pulmonary lesions. Respirology (2011) 0.91
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration. Ann Pharmacother (2010) 0.91
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol (2011) 0.91
Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother (2004) 0.91
Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr (2002) 0.90
Lack of a correlation between portal vein flow and pressure: toward a shared interpretation of hemodynamic stress governing inflow modulation in liver transplantation. Liver Transpl (2011) 0.89
Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals. Antivir Ther (2005) 0.89
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. Antivir Ther (2010) 0.89
Platelet lysate mucohadesive formulation to treat oral mucositis in graft versus host disease patients: a new therapeutic approach. AAPS PharmSciTech (2011) 0.89
Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort. J Antimicrob Chemother (2005) 0.88
Predictors of AIDS-defining events among advanced naïve patients after HAART. HIV Clin Trials (2007) 0.86
Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART. J Med Virol (2003) 0.85
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART. J Med Virol (2008) 0.85
The Italian version of the Glaucoma Symptom Scale Questionnaire: translation, validation, and reliability. J Glaucoma (2013) 0.84
[Prevalence of Plasmodium spp. in asymptomatic African immigrants assessed by nucleic acid sequence based amplification]. Infez Med (2010) 0.84
Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen). J Acquir Immune Defic Syndr (2004) 0.84
Systemic Inflammation-Based Biomarkers and Survival in HIV-Positive Subject With Solid Cancer in an Italian Multicenter Study. J Acquir Immune Defic Syndr (2015) 0.84
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. Antivir Ther (2006) 0.84
Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy. J Antimicrob Chemother (2012) 0.83
Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. Am J Kidney Dis (2004) 0.83
Human granulocytic anaplasmosis in northeastern Italy. Ann N Y Acad Sci (2006) 0.83
Aeromonas sobria sepsis complicated by rhabdomyolysis in an HIV-positive patient: case report and evaluation of traits associated with bacterial virulence. Int J Infect Dis (2008) 0.83
Response and survival of patients with chronic graft-versus-host disease treated by extracorporeal photochemotherapy: a retrospective study according to classical and National Institutes of Health classifications. Transfusion (2012) 0.83
Chronic inflammation in a long-term cohort of HIV-infected patients according to the normalization of the CD4:CD8 ratio. AIDS Res Hum Retroviruses (2014) 0.83
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received. AIDS Res Ther (2012) 0.82
Both a protective and a deleterious role for the L76V mutation. Antimicrob Agents Chemother (2009) 0.82
Ocular surface disease and glaucoma: how to evaluate impact on quality of life. J Ocul Pharmacol Ther (2012) 0.82
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients. J Acquir Immune Defic Syndr (2015) 0.82
Limiting severe outcomes and impact on intensive care units of moderate-intermediate 2009 pandemic influenza: role of infectious diseases units. PLoS One (2012) 0.82
Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination. Expert Opin Pharmacother (2010) 0.81
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy. AIDS Patient Care STDS (2007) 0.81
Mononuclear cell collection for extracorporeal photochemotherapy: a study comparing an automatic and a semiautomatic apheresis device. Transfusion (2013) 0.81
Clinical experience with daptomycin in Italy: results from a registry study of the treatment of Gram-positive infections between 2006 and 2009. J Chemother (2012) 0.81
Platelet lysate formulations based on mucoadhesive polymers for the treatment of corneal lesions. J Pharm Pharmacol (2010) 0.81